phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Assessment of HER2 Status in Extramammary Paget Disease and Its Implication for Disitamab Vedotin, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate Therapy

Researchers from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking University Cancer Hospital & Institute, et al. have conducted a paper entitled "Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy". This study was published in Frontiers of Medicine, Volume 18, Issue 3.

November 7, 2025


November 7 2025

November 6 2025

November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy